Janux Therapeutics (NASDAQ:JANX) Shares Gap Up to $44.62

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) gapped up prior to trading on Thursday . The stock had previously closed at $44.62, but opened at $47.06. Janux Therapeutics shares last traded at $52.00, with a volume of 640,405 shares traded.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on JANX. Cantor Fitzgerald began coverage on Janux Therapeutics in a research report on Wednesday, March 20th. They issued an “overweight” rating and a $100.00 price objective on the stock. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research report on Tuesday, February 27th. BTIG Research started coverage on Janux Therapeutics in a research report on Thursday, March 21st. They issued a “buy” rating and a $62.00 price objective on the stock. Bank of America lifted their price target on Janux Therapeutics from $24.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, March 13th. Finally, Wedbush restated an “outperform” rating and set a $53.00 price target on shares of Janux Therapeutics in a research report on Monday, March 11th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $59.60.

Janux Therapeutics Stock Up 5.3 %

The company has a market capitalization of $2.72 billion, a P/E ratio of -39.29 and a beta of 4.18. The company has a 50-day moving average of $31.14 and a two-hundred day moving average of $16.72.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Friday, March 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.12. The business had revenue of $2.46 million during the quarter, compared to analysts’ expectations of $0.98 million. Janux Therapeutics had a negative return on equity of 17.88% and a negative net margin of 721.18%. As a group, equities analysts expect that Janux Therapeutics, Inc. will post -1.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in JANX. Nisa Investment Advisors LLC raised its stake in Janux Therapeutics by 10,740.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock valued at $29,000 after buying an additional 2,685 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Janux Therapeutics by 149.4% in the first quarter. Tower Research Capital LLC TRC now owns 3,344 shares of the company’s stock worth $40,000 after purchasing an additional 2,003 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Janux Therapeutics in the fourth quarter worth $57,000. Barclays PLC raised its stake in shares of Janux Therapeutics by 533.0% in the fourth quarter. Barclays PLC now owns 4,608 shares of the company’s stock worth $61,000 after purchasing an additional 3,880 shares during the last quarter. Finally, Citigroup Inc. raised its stake in shares of Janux Therapeutics by 935.2% in the second quarter. Citigroup Inc. now owns 5,787 shares of the company’s stock worth $69,000 after purchasing an additional 5,228 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.